The investment will be used to complete three phase II clinical trials in which the efficacy of its most advanced products is being studied, namely PBF-680 in patients with chronic obstructive pulmona...
Read moreLos últimos resultados obtenidos refuerzan la idea de que las recomendaciones nutricionales deben tener en cuenta patrones generales de dieta más que alimentos individuales, y confirman que adoptar ...
Read moreIt has been developed a bioinformatics tool for estimating the genetic risk of suffering common diseases such as diabetes, heart attacks or cancer in a certain population.
Read moreResults of exploratory research from the open-label phase III INTRIGUE clinical trial demonstrate the potential utility of circulating tumor DNA (ctDNA) next-generation sequencing (NGS)-based analysis...
Read moreThe study reveals that GDF15 inhibits glucose synthesis in the liver. This pathway plays a decisive role in the generation of hyperglycaemia (increased blood glucose levels) in patients with type 2 di...
Read more2023 in biomedical research has been full of incredible advances that bring us, step by step, closer to the future. From the production of green fertilisers that reduce their impact on the environment...
Read moreThe project to create the XNA-HUB platform receives a significant boost thanks to PERTE funding. The platform will design therapeutic molecules based on modified nucleic acids using supercomputing tec...
Read moreThis technology makes it possible to evaluate the efficacy of drugs in biological models that represent at the microscale the conditions under which a tumor develops in the human body.
Read moreEl Instituto de Investigación Sanitaria La Fe (IIS La Fe) ha puesto en marcha un ensayo clínico para mejorar la supervivencia de pacientes diagnosticados con neuroblastoma de alto riesgo en España ...
Read moreMás de 130 niñas y adolescentes diagnosticadas en el Hospital Sant Joan de Déu de un tumor del desarrollo en que el tratamiento podía comprometer su fertilidad futura han sido intervenidas para ex...
Read moreThe new immunotherapy is based on the so-called STAb cells. It has yet to pass clinical trials and therefore it will be at least two years before it reaches the patients.
Read moreLos científicos han identificado un ARN, al que han denominado lncREST (long non-coding RNA REplication STress), y han desvelado su papel en la activación de una respuesta efectiva al estrés induci...
Read more